AzTrials
AzTrials

Advanced Solid TumorLIQPLATNCT06367751

Implementation of Liquid Biopsies During Routine Clinical Care in Patients With Advanced Malignancies (LIQPLAT)

A study testing ctDNA measurement in people with Advanced Solid Tumor, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The goal of this study is to assess the implementation and feasibility of ctDNA measurements from blood samples obtained during routine clinical care of cancer patients in the University Hospital Basel. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Advanced Solid Tumor
What is being tested?
ctDNA measurement
Could I receive a placebo?
No, everyone receives an active treatment
How many people
159 participants
Where
1 siteSwitzerland
Study dates
2 May 2024to Oct 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients with a proven solid malignant disease, i.e. with solid malignant tumors where no primary surgical resection is planned OR solid malignant tumors that are locally advanced and inoperable OR solid tumors that are metastatic
  • No prior treatment for advanced/metastatic disease
  • Indication for medical anti-cancer treatment (including combined chemoradiotherapy) as judged by the treating physician
  • Patient age 18 years and older
  • General research consent of the University Hospital Basel

Who cannot join

  • ● Patients with primary brain tumors

Trial locations and contacts

1 site in 1 country.

Switzerland1 site

  • Department of Medical Oncology, University Hospital Basel

    Basel, 4031

Other trials in Switzerland

About this study

The goal of this study is to assess the implementation and feasibility of ctDNA measurements from blood samples obtained during routine clinical care of cancer patients in the University Hospital Basel.

Researchers will compare clinical and patient reported outcomes from the LIQPLAT study with patients who did not receive ctDNA measurements (external comparator from registry AO_2023-00091).

Blood samples will be drawn from the patients as part of routine care and ctDNA measurements will be performed on these samples.

Read the detailed description

Liquid biopsies, in particular the analysis of circulating tumor DNA (ctDNA), have emerged as a promising tool for detecting and monitoring cancer. Measuring ctDNA in patients with solid malignancies may help to identify targetable alterations, measure disease burden, identify early mutations of resistance, tailor and deescalate cancer treatment, and predict patient prognosis. Although the adoption and application of ctDNA measurements for patients with solid tumors in routine clinical care is increasing, evidence supporting the integration of ctDNA into current practice is limited, especially for patients with advanced cancers.

This is a trial using routinely collected health care data from an ongoing registry (AO_2023-00091) in cancer patients with advanced solid malignancies receiving first line systemic anticancer treatment for advanced disease.

This trial will assess the feasibility and implementation of routine measurement of ctDNA and its association with clinical outcomes, including quality of life and survival. All patients will receive routine diagnostics, treatment and follow-up. All patients with a new cancer diagnosis will be assessed for eligibility based on the routinely collected information available in the registry. We will then randomly decide which eligible patients are invited to participate in the trial. If patients accept the invitation and intend to get a measurement of ctDNA, they have to provide written informed consent.

Results from ctDNA analyses will be discussed at the molecular tumor board, an established regular interdisciplinary meeting at the University Hospital Basel (part of routine care) to discuss patients with complex findings from tumor sequencing analyses. Treatment changes occurring during the trial duration will be at the discretion of treating physician and according to patient's preference as is routine standard of care.

Being tested
ctDNA measurement
Keywords
ctDNA

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ctDNA measurementDiagnostic test

    Blood samples are collected as part of standard of care and ctDNA measurements will be performed on these samples.

Study groups in NCT06367751
Study groupRoleWhat they receive
Active ComparatorExperimentalPatients included in the ongoing registry AO_2023-00091. Patients will have ctDNA measurements being performed on blood samples collected as part of clinical routine.
Receives: Diagnostic Test: ctDNA measurement

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number and proportion of patients in whom ctDNA was detectable before starting medical anticancer treatment

    Number and proportion of patients in whom ctDNA was detectable before starting medical anticancer treatment. Calculated as the number of patients with detectable ctDNA over the total number of patients included, expressed as a percentage.

    Measured: 1 time assessment at baseline

  2. Patients in whom actionable alterations were identified in ctDNA analysis

    Patients in whom actionable alterations were identified in ctDNA analysis. Calculated as the number of patients with actionable alterations over the total number of patients included, expressed as a percentage.

    Clinical event is defined as suspicious or confirmed clinical or radiological disease progression or treatment discontinuation for any reason.

    Measured: baseline, between month 2 and 3, between month 5 and 6, clinical event

  3. Turn-around time of ctDNA analysis

    Time from ctDNA request until issuing the first report. Expressed as hours.

    Clinical event is defined as suspicious or confirmed clinical or radiological disease progression or treatment discontinuation for any reason.

    Measured: baseline, between month 2 and 3, between month 5 and 6, clinical event

  4. ctDNA kinetics

    Change in allelic frequency over time including relative changes from baseline.

    Measured: up to 24 months

Secondary outcomes (10)

  1. Number of ctDNA testing results that were successfully made available to the molecular tumor board

    Number of ctDNA testing results that were successfully made available to the molecular tumor board.

    Measured: up to 24 months

  2. Number of patients being positive for ctDNA and suspicious Clonal Hematopoiesis of Indeterminate Potential

    Number of patients being positive for ctDNA and suspicious Clonal Hematopoiesis of Indeterminate Potential

    Measured: up to 24 months

  3. Quality of life and physical function

    Global quality of life and physical function as measured by EORTC QLQ C30 and C15 (European Organisation for Research and Treatment of Cancer, Quality of Life Questionnaire). Calculation of the scores follows the validated formulas as issued by the EORTC. Scores range from 0% to 100% for all domains with higher values representing better outcome.

    Measured: month 3, month 6, month 12

  4. Overall survival

    Overall survival.

    Measured: up to 24 months

  5. Survival rate 6 months

    Survival rate 6 months.

    Measured: Month 6

  6. Survival rate 12 months

    Survival rate 12 months.

    Measured: Month 12

  7. Time to next treatment line

    Time to next treatment line, expressed in days.

    Measured: up to 24 months

  8. Unplanned hospital admissions and emergency room visits

    Number and proportion of unplanned hospital admissions and emergency room visits.

    Measured: up to 24 months

  9. Progression free survival

    Progression free survival as determined by routine imaging (e.g. CT scan, MRI), tumor marker (e.g. PSA). Defined as time from date of informed consent until disease progression or death, whatever occurs first.

    Measured: up to 24 months

  10. Number of ctDNA analyses with a valid result

    Number of ctDNA analyses with a valid result - that is all ctDNA analyses conducted without any observed technical errors.

    Measured: up to 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Apr 2024
  2. Study start2 May 2024
  3. Primary completionOct 2026 (estimated)
  4. Study completionOct 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Model description
This is a trial using routinely collected health care data from an ongoing registry (AO\_2023-00091) in cancer patients with advanced solid malignancies receiving first line systemic anti-cancer treatment for advanced disease. All patients will receive routine diagnostics, treatment and follow-up. All patients with a new cancer diagnosis will be assessed for eligibility based on the routinely collected information available in the registry. We will then randomly decide which eligible patients are invited to participate in the trial. If patients accept the invitation and intend to get a measurement of ctDNA, they have to provide written informed consent. The study comprises an external comparator arm with 75 (anticipated) cancer patients, and an active comparator arm with 150 (anticipated) cancer patients.
Masking
None (open label)
Enrolment
159 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06367751
Sponsor's protocol ID
2024-00358; th23Kasenda
Acronym
LIQPLAT
Status last verified
Sep 2025
First submitted
11 Apr 2024
Last updated
11 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data will be shared upon reasonable request following SPHN (https://sphn.ch/) guidelines for data sharing.

Publications

  • Schwenke JM, Schmitt AM, McLennan S, Janiaud P, Laubli H, Binder M, Alborelli I, Matter MS, Hinke J, Widmer CC, Hemkens LG, Kasenda B, Briel M. Mixed-methods process evaluation of ctDNA use to guide decision-making in patients with advanced solid cancers: study protocol for a substudy of the LIQPLAT trial. BMJ Open. 2025 Oct 28;15(10):e100537. doi: 10.1136/bmjopen-2025-100537.

    PubMed 41151945

Questions about this trial

What is this clinical trial studying?

A study testing ctDNA measurement in people with Advanced Solid Tumor, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 11 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number and proportion of patients in whom ctDNA was detectable before starting medical anticancer treatment (time frame: 1 time assessment at baseline). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06367751, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Mar 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in